Tibor Keler

11.0k citations

153 papers · 6.0k indexed · 1 hit paper · h-index 46

Impact in

Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research

Papers in

Immunology 108
- Immunotherapy and Immune Responses 72
- Immune Cell Function and Interaction 35
- T-cell and B-cell Immunology 28
- Immune Response and Inflammation 9
Oncology 75
- Cancer Immunotherapy and Biomarkers 53
- CAR-T cell therapy research 36

Co-authors: Laura Vitale Venky Ramakrishna Michael Yellin Li-Zhen He Robert F. Graziano Thomas A. Davis Paul K. Wallace Michael W. Fanger
Journals: Journal of Clinical Oncology (20 papers)The Journal of Immunology (16 papers)Cancer Research (13 papers)Blood (11 papers)Journal for ImmunoTherapy of Cancer (8 papers)
Partner nations: United States United Kingdom Netherlands

In The Last Decade

Tibor Keler

150 papers receiving 5.9k citations

Hit Papers

align trajectories log scale

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study 2015 · 313 citations

Peers

Countries citing papers authored by Tibor Keler

Since Specialization

Citations

This map shows the geographic impact of Tibor Keler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tibor Keler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tibor Keler more than expected).

Fields of papers citing papers by Tibor Keler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tibor Keler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tibor Keler. The network helps show where Tibor Keler may publish in the future.

Co-authors

The 25 scholars most cited alongside Tibor Keler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tibor Keler Line = papers co-authored together Tibor Keler links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX ‐622 Allergy ·Miles Murphy, Laura Vitale, Thomas J. O’Neill, Deena M. Maurer, Linda Malenchek, Andrea Crocker, Colleen Patterson, Laura Mills‐Chen, Virginia Saley, Nicole M. Antczak, James M. Boyer, Kelly M. McManus, Noe Rico Montanari, Russell A. Hammond, J. Goldstein, Lawrence J. Thomas, Tibor Keler, Diego Alexander Garzón Alvarado	2025	2
2	Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study Allergy ·Diego Alvarado, Marcus Maurer, Richard Gedrich, Scott B. Seibel, Michael Murphy, Linda Crew, J. Goldstein, Andrea Crocker, Laura Vitale, Pamela A. Morani, Lawrence J. Thomas, Thomas Hawthorne, Tibor Keler, Diane Young, Elizabeth Crowley, Martin Kankam, Margo Heath‐Chiozzi	2022	62
3	Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering Communications Biology ·Franziska Heckel, Anna H. Turaj, Hayden Fisher, H.T. Claude Chan, Michael J. Marshall, Osman Dadas, Christine A. Penfold, Tatyana Inzhelevskaya, C. Ian Mockridge, Diego Alvarado, Ivo Tews, Tibor Keler, Stephen A. Beers, Mark S. Cragg, Sean H. Lim	2022	12
4	Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice Cancer Immunology Immunotherapy ·Anna Wasiuk, Jeff Weidlick, Crystal Sisson, Jenifer Widger, Andrea Crocker, Laura Vitale, Henry C. Marsh, Tibor Keler, Li-Zhen He	2021	4
5	A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells The Journal of Immunology ·Takaaki Oba, Toshifumi Hoki, Takayoshi Yamauchi, Tibor Keler, Henry C. Marsh, Xuefang Cao, Fumito Ito	2020	27
6	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s Nature Communications ·Takaaki Oba, Mark D. Long, Tibor Keler, Henry C. Marsh, Hans Minderman, Scott I. Abrams, Song Liu, Fumito Ito	2020	105
7	Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies Blood Advances ·Stephen M. Ansell, Ian W. Flinn, Matthew H. Taylor, Branimir I. Šikić, Joshua Brody, John Nemunaitis, Andrew L. Feldman, Thomas Hawthorne, Tracey Rawls, Tibor Keler, Michael Yellin	2020	52
8	Development and Characterization of a Preclinical Model for the Evaluation of CD205-Mediated Antigen Delivery Therapeutics in Type 1 Diabetes ImmunoHorizons ·Jennifer Schloss, Riyasat Ali, Jeffrey Babad, Ignacio Guerrero‐Ros, Jillamika Pongsachai, Li-Zhen He, Tibor Keler, Teresa P. DiLorenzo	2019	2
9	PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity Clinical Cancer Research ·Sarah L. Buchan, Mohannad Fallatah, Stephen M. Thirdborough, Vadim Y. Taraban, Anne Rogel, Lawrence J. Thomas, Christine A. Penfold, Li-Zhen He, Michael A. Curran, Tibor Keler, Aymen Al‐Shamkhani	2018	82
10	CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response OncoImmunology ·Katherine A. Riccione, Li-Zhen He, Peter E. Fecci, Pamela K. Norberg, Carter M. Suryadevara, Adam M. Swartz, Patrick Healy, Elizabeth A. Reap, Tibor Keler, Qi-Jing Li, Kendra L. Congdon, Luis Sánchez-Pérez, John H. Sampson	2018	10
11	Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy Cancer Immunology Immunotherapy ·Laura Vitale, Lawrence J. Thomas, Li-Zhen He, Thomas J. O’Neill, Jenifer Widger, Andrea Crocker, Karuna Sundarapandiyan, James R. Storey, Eric M. Forsberg, Jeffrey Weidlick, April R. Baronas, Lauren E. Gergel, James M. Boyer, Crystal Sisson, J. Goldstein, Henry C. Marsh, Tibor Keler	2018	39
12	CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy The Journal of Immunology ·Anna Wasiuk, James Testa, Jeff Weidlick, Crystal Sisson, Laura Vitale, Jenifer Widger, Andrea Crocker, Lawrence J. Thomas, J. Goldstein, Henry C. Marsh, Tibor Keler, Li-Zhen He	2017	40
13	In Situ Vaccination Improves Efficacy of PD-1 Blockade in Unresponsive Lymphoma Tumors through Induction of a Highly Efficient Cross-Presenting Dendritic Cell Subset Expressing TLR3 Blood ·Linda Hammerich, Maxime Dhainaut, Tibor Keler, Thomas A. Davis, Andres Μ. Salazar, Brian D. Brown, Joshua Brody	2017	1
14	Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1 Molecular Cancer Therapeutics ·Lawrence J. Thomas, Laura Vitale, Thomas J. O’Neill, Ree Y. Dolnick, Paul K. Wallace, Hans Minderman, Lauren E. Gergel, Eric M. Forsberg, James M. Boyer, James R. Storey, Catherine D. Pilsmaker, Russell A. Hammond, Jenifer Widger, Karuna Sundarapandiyan, Andrea Crocker, Henry C. Marsh, Tibor Keler	2016	34
15	Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients Clinical Cancer Research ·Michael A. Morse, Robert Chapman, John D. Powderly, Kimberly Blackwell, Tibor Keler, Jennifer Green, Renee Riggs, Li-Zhen He, Venky Ramakrishna, Laura Vitale, Biwei Zhao, Stephen A. Butler, Amy Hobeika, Takuya Osada, Thomas A. Davis, Timothy Clay, H. Kim Lyerly	2011	112
16	Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti–human DEC205 monoclonal antibody Blood ·Cheolho Cheong, Jae‐Hoon Choi, Laura Vitale, Li-Zhen He, Christine Trumpfheller, Leonia Bozzacco, (unknown), Godwin Nchinda, Sung Ho Park, Durga Bhavani Dandamudi, Elina Shrestha, Maggi Pack, Han‐Woong Lee, Tibor Keler, Ralph M. Steinman, Chae Gyu Park	2010	100
17	Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity Cancer Research ·Eduardo Huarte, Juan R. Cubillos‐Ruiz, Yolanda C. Nesbeth, Uciane K. Scarlett, Diana G. Martinez, Ronald J. Buckanovich, Fabián Benencia, Radu V. Stan, Tibor Keler, Pablo Sarobe, Charles L. Sentman, José R. Conejo-García	2008	96
18	Targeting antigens to the human mannose receptor expressed in transgenic mice elicits potent CD4 and CD8 responses in vivo Cancer Research ·Li-Zhen He, Andrea Crocker, Laura Vitale, Thomas J. O’Neill, Raphael Clynes, Tibor Keler	2006	1
19	Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210 Breast Cancer Research and Treatment ·Michiaki Watanabe, Paul K. Wallace, Tibor Keler, Yashwant M. Deo, Charuwan Akewanlop, Daniel F. Hayes	1999	46
20	Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. PubMed ·Tibor Keler, R F Graziano, Arabinda Mandal, Paul K. Wallace, James L. Fisher, Paul M. Guyre, Michael W. Fanger, Yashwant M. Deo	1997	51

About Tibor Keler

Tibor Keler is a scholar working on Immunology, Oncology, Radiology, Nuclear Medicine and Imaging, Immunology and Allergy and Virology, having authored 153 papers that have together received 6.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (72 papers), Cancer Immunotherapy and Biomarkers (53 papers), Monoclonal and Polyclonal Antibodies Research (48 papers), CAR-T cell therapy research (36 papers), Immune Cell Function and Interaction (35 papers), T-cell and B-cell Immunology (28 papers), Glycosylation and Glycoproteins Research (21 papers) and Immune Response and Inflammation (9 papers). The work is most often cited by research in Immunology (4.2k citations), Oncology (2.4k citations), Radiology, Nuclear Medicine and Imaging (974 citations), Virology (190 citations) and Genetics (404 citations). Tibor Keler has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Laura Vitale, Venky Ramakrishna, Michael Yellin, Li-Zhen He, Robert F. Graziano, Thomas A. Davis, Paul K. Wallace, Michael W. Fanger, Yashwant M. Deo and Henry C. Marsh. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Immunology, Cancer Research, Blood and Journal for ImmunoTherapy of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact